2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

Yi-Heng Li, Chih Yuan Fang, I. Chang Hsieh, Wei Chun Huang, Tsung Hsien Lin, Shih Hsien Sung, Chiung Zuan Chiu, Chiung Jen Wu, Kou Gi Shyu, Po Yuan Chang, Ching Chang Fang, Tse Min Lu, Ching Pei Chen, Wei Chen Tai, Chau Chyun Sheu, Kai Che Wei, Yi Hsiu Huang, Hsing Mei Wu, Juey Jen Hwang

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

Original languageEnglish
Pages (from-to)201-210
Number of pages10
JournalActa Cardiologica Sinica
Volume34
Issue number3
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Acute Coronary Syndrome
Taiwan
Platelet Aggregation Inhibitors
Ecchymosis
Hemorrhage
Therapeutics
Safety
Epistaxis
Hematuria
Dyspnea
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Li, Yi-Heng ; Fang, Chih Yuan ; Hsieh, I. Chang ; Huang, Wei Chun ; Lin, Tsung Hsien ; Sung, Shih Hsien ; Chiu, Chiung Zuan ; Wu, Chiung Jen ; Shyu, Kou Gi ; Chang, Po Yuan ; Fang, Ching Chang ; Lu, Tse Min ; Chen, Ching Pei ; Tai, Wei Chen ; Sheu, Chau Chyun ; Wei, Kai Che ; Huang, Yi Hsiu ; Wu, Hsing Mei ; Hwang, Juey Jen. / 2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan. In: Acta Cardiologica Sinica. 2018 ; Vol. 34, No. 3. pp. 201-210.
@article{fc76ce25a6654014905a5222854db448,
title = "2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan",
abstract = "Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.",
author = "Yi-Heng Li and Fang, {Chih Yuan} and Hsieh, {I. Chang} and Huang, {Wei Chun} and Lin, {Tsung Hsien} and Sung, {Shih Hsien} and Chiu, {Chiung Zuan} and Wu, {Chiung Jen} and Shyu, {Kou Gi} and Chang, {Po Yuan} and Fang, {Ching Chang} and Lu, {Tse Min} and Chen, {Ching Pei} and Tai, {Wei Chen} and Sheu, {Chau Chyun} and Wei, {Kai Che} and Huang, {Yi Hsiu} and Wu, {Hsing Mei} and Hwang, {Juey Jen}",
year = "2018",
month = "5",
day = "1",
doi = "10.6515/ACS.201805_34(3).20180302A",
language = "English",
volume = "34",
pages = "201--210",
journal = "Acta Cardiologica Sinica",
issn = "1011-6842",
publisher = "Republic of China Society of Cardiology",
number = "3",

}

Li, Y-H, Fang, CY, Hsieh, IC, Huang, WC, Lin, TH, Sung, SH, Chiu, CZ, Wu, CJ, Shyu, KG, Chang, PY, Fang, CC, Lu, TM, Chen, CP, Tai, WC, Sheu, CC, Wei, KC, Huang, YH, Wu, HM & Hwang, JJ 2018, '2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan', Acta Cardiologica Sinica, vol. 34, no. 3, pp. 201-210. https://doi.org/10.6515/ACS.201805_34(3).20180302A

2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan. / Li, Yi-Heng; Fang, Chih Yuan; Hsieh, I. Chang; Huang, Wei Chun; Lin, Tsung Hsien; Sung, Shih Hsien; Chiu, Chiung Zuan; Wu, Chiung Jen; Shyu, Kou Gi; Chang, Po Yuan; Fang, Ching Chang; Lu, Tse Min; Chen, Ching Pei; Tai, Wei Chen; Sheu, Chau Chyun; Wei, Kai Che; Huang, Yi Hsiu; Wu, Hsing Mei; Hwang, Juey Jen.

In: Acta Cardiologica Sinica, Vol. 34, No. 3, 01.05.2018, p. 201-210.

Research output: Contribution to journalReview article

TY - JOUR

T1 - 2018 expert consensus on the management of adverse effects of antiplatelet therapy for acute coronary syndrome in Taiwan

AU - Li, Yi-Heng

AU - Fang, Chih Yuan

AU - Hsieh, I. Chang

AU - Huang, Wei Chun

AU - Lin, Tsung Hsien

AU - Sung, Shih Hsien

AU - Chiu, Chiung Zuan

AU - Wu, Chiung Jen

AU - Shyu, Kou Gi

AU - Chang, Po Yuan

AU - Fang, Ching Chang

AU - Lu, Tse Min

AU - Chen, Ching Pei

AU - Tai, Wei Chen

AU - Sheu, Chau Chyun

AU - Wei, Kai Che

AU - Huang, Yi Hsiu

AU - Wu, Hsing Mei

AU - Hwang, Juey Jen

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

AB - Antiplatelet therapy is a key component in the treatment of acute coronary syndrome (ACS). The management of ACS has evolved considerably over recent years with the development of new and more potent antiplatelet agents. Clinical trials on ACS have demonstrated that potent antiplatelet agents can more effectively reduce cardiovascular events. However, there is a tipping point between safety and efficacy, beyond which the risk of bleeding and other adverse effects can outweigh the benefits of antiplatelet therapy. Striking a balance between safety and efficacy remains a major challenge. A consensus meeting of an expert panel composed of Taiwanese experts was held to provide recommendations for the management of adverse effects in patients with ACS receiving antiplatelet therapy. The common adverse effects of antiplatelet therapy include upper gastrointestinal bleeding, ecchymosis, hematuria, epistaxis and ticagrelor-related dyspnea. In this study, a literature review of these adverse events was performed and recommendations for the management were made.

UR - http://www.scopus.com/inward/record.url?scp=85047087310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047087310&partnerID=8YFLogxK

U2 - 10.6515/ACS.201805_34(3).20180302A

DO - 10.6515/ACS.201805_34(3).20180302A

M3 - Review article

AN - SCOPUS:85047087310

VL - 34

SP - 201

EP - 210

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

SN - 1011-6842

IS - 3

ER -